News | Radiation Therapy | May 05, 2017

CyberKnife System Provides Effective Treatment Option for Early-Stage Breast Cancer Patients

Robotic radiosurgery system's motion management technique limits toxicity and preserves cosmesis in convenient, five-fraction treatment regimen

CyberKnife System Provides Effective Treatment Option for Early-Stage Breast Cancer Patients

May 5, 2017 — Accuray Inc. announced preliminary results from a prospective, phase I clinical trial evaluating adjuvant stereotactic partial breast irradiation (S-PBI) in early-stage breast cancer patients treated with the CyberKnife System. The study, published in the May issue of the peer-reviewed International Journal of Radiation Oncology - Biology - Physics, reported no recurrences or distant metastases at median follow-up of 26 months. Additionally, at two years, more than 95 percent of patients and 100 percent of physicians rated cosmesis as excellent or good, indicating both patients and physicians were satisfied with the appearance of the breast following treatment.

"The results of this phase 1 study highlight a new approach for treating breast cancer while minimizing tissue exposure. We believe our protocol offers reproducible and executable guidance for other radiation therapy teams interested in incorporating S-PBI into their practice," said Asal Rahimi, M.D., M.S., assistant professor of radiation oncology, University of Texas Southwestern Medical Center, in Dallas, Texas. "Our study shows the benefits of real-time image guidance and motion control when delivering S-PBI."

The study, titled, "Preliminary Results of a Phase 1 Dose Escalation Trial for Early Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial Breast Irradiation (S-PBI)," provides results for 75 patients treated with S-PBI following lumpectomy. It showed:

  • Real-time image guidance and motion control with the Synchrony Respiratory Tracking System enabled precise treatments, ultimately limiting toxicity and preserving cosmesis;
  • Dose escalation to 40 Gy/5 fractions is possible without exceeding the maximum tolerated dose. Treatments provided tumor control with minimal acute or late side effects; and
  • S-PBI provides a more convenient treatment option than hypofractionated whole-breast irradiation (NCCN guideline: 40-42.5 Gy over 15-16 fractions), with no compromise in tolerability or short-term efficacy.

The CyberKnife System enables precise dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. CyberKnife technology continually tracks and automatically adjusts the beam for movement in real-time, as the patient breathes normally, throughout the entire treatment session. The system's sub-millimeter accuracy enhances clinicians' abilities to treat effectively while preserving healthy tissue.

The purpose of this prospective, phase I study was to evaluate the maximum tolerated dose (MDT) of five fraction stereotactic body radiation therapy for partial breast irradiation (S-PBI) in treating early stage-breast cancer after lumpectomy. All patients were treated with the CyberKnife System, which delivers non-isocentric and non-coplanar radiation beams. Patient follow-up occurred every three months for year 1 and every six months until year 5. Longer follow-up and additional Phase II/III data are required to follow late toxicities, control, and determination of the optimal dose to be considered for standard use.

For more information: www.accuray.com

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...